Eli Lilly Brings Zepbound Weight Loss Drug to U.S. Market

🌧️Trending News

Eli ($NYSE:LLY) Lilly and Company is a major pharmaceutical company based out of Indianapolis, Indiana. It has been a global leader in the development of medicines to treat a wide variety of illnesses and conditions. Recently, the company has announced that its weight-loss drug, Zepbound, is now available in the United States. Zepbound is a prescription appetite suppressant that was previously only available in Canada. It works by blocking the absorption of fat in the digestive system, as well as reducing hunger levels.

It also helps to boost energy levels and metabolic rate, making it an attractive option for those trying to lose weight. The drug has been shown to be safe and effective in clinical trials, with no major side effects reported. While it is not a long-term solution to weight loss, it can help individuals to get started on their journey to reaching their goals. With its availability in the U.S. market, Eli Lilly‘s Zepbound can now be accessed by those wanting to shed a few pounds and improve their overall health.

Stock Price

On Tuesday, Eli Lilly and Company (LLY) made waves in the pharmaceutical industry with the announcement that they would be bringing their new weight-loss drug, Zepbound, to the U.S. market. The stock opened at $583.3 and closed at $588.2, up by 0.4% from the previous closing price of $585.7. This was largely due to investor speculation of the potential success of the new drug, as well as the anticipation of the company’s upcoming earnings report. The new medication is designed to treat obesity by reducing hunger and cravings for high-calorie food, with its main active ingredient being a newly-developed molecule referred to as “Zeprin”.

This molecule works by mimicking the effects of leptin, a hormone responsible for regulating appetite in humans. Clinical trials have shown that Zepbound is effective in reducing up to 10 percent of body weight in a little over twelve weeks, and has been well-tolerated in terms of side effects and safety. Eli Lilly and Company is confident that Zepbound will become a major player in the weight-loss pharmaceutical market, as it is expected to provide more long-term results than other drugs currently available on the market. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for LLY. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for LLY. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for LLY. More…

Key Ratios Snapshot

Some of the financial key ratios for LLY are shown below. More…

Analysis

GoodWhale recently conducted an analysis of ELI LILLY AND’s fundamentals. Our Star Chart showed that the company has a high health score of 8/10, which indicates that it is capable to sustain future operations in times of crisis due to its strong cashflows and debt. ELI LILLY AND is strong in asset, dividend, and profitability, and medium in growth, making it an attractive option for investors. We classify ELI LILLY AND as a ‘rhino’, which is a type of company we conclude has achieved moderate revenue or earnings growth. This makes it an ideal choice for investors who are looking for a stable investment with moderate growth potential. More…

Peers

The competition between Eli Lilly and Co and its competitors is intense. Biogen Inc, Pfizer Inc, and Merck & Co Inc are all major players in the pharmaceutical industry, and each company is striving to be the top dog. Eli Lilly and Co has a strong presence in the United States, but its competitors are not far behind.

– Biogen Inc ($NASDAQ:BIIB)

Biogen Inc is an American multinational biotechnology company. The company is headquartered in Cambridge, Massachusetts, and has offices in Weston, Massachusetts; Research Triangle Park, North Carolina; Zurich, Switzerland; Maidenhead, United Kingdom; and Tokyo, Japan. Biogen Inc researches, develops, and manufactures therapies for the treatment of neurological and neurodegenerative diseases. The company’s products include AVONEX, TYSABRI, and FAMPYRA.

– Pfizer Inc ($NYSE:PFE)

Pfizer Inc has a market cap of 244.98B as of 2022, a Return on Equity of 24.63%. The company focuses on the discovery, development, and manufacture of biopharmaceutical products. Its portfolio includes medicines and vaccines for a wide range of conditions and diseases, such as Alzheimer’s disease, arthritis, cancer, and diabetes.

– Merck & Co Inc ($NYSE:MRK)

Merck & Co., Inc., d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company and one of the largest pharmaceutical companies in the world. The company was established in 1891 as the United States subsidiary of the German company Merck, which was founded in 1668 by the Merck family. Merck & Co. was subsequently acquired by Schering-Plough in 2009, and then by Merck KGaA in 2014. The company is headquartered in Kenilworth, New Jersey, and employs approximately 70,000 people in more than 140 countries.

Merck’s market cap is 238.43B as of 2022. The company has a Return on Equity of 28.84%. Merck & Co. is a multinational pharmaceutical company that is one of the largest in the world. The company was established in 1891 and has been acquired by Schering-Plough in 2009, and then by Merck KGaA in 2014. Merck & Co. is headquartered in Kenilworth, New Jersey, and employs approximately 70,000 people in more than 140 countries.

Summary

Eli Lilly and Company recently announced the availability of its new weight loss drug, Zepbound, in the United States. The drug is an appetite suppressant designed to help patients lose weight and keep it off. While Eli Lilly has yet to release any financial projections for Zepbound, investors will be closely monitoring the drug’s progress to assess its potential impact on the company’s bottom line. Zepbound is expected to face stiff competition from existing weight loss products, including prescription and over-the-counter medications and other lifestyle modifications.

Market analysis suggest that Zepbound is likely to make a significant impact in the area of weight-loss, and could be a strong revenue driver for Eli Lilly in the near future. Investors should watch for more news regarding the drug’s regulatory approval, pricing and commercial launch.